Elevated Hb A<inf>2</inf> levels in a patient with a compound heterozygosity for the (β <sup>+</sup>)-31 (A > G) and (β <sup>0</sup>) Codon 17 (A > T) mutations together with a single α-globin gene

• Main Authors: Sitthichai Panyasai, Kanokwan Jaiping, Sakorn Pornprasert
• Format: Journal
• Published: 2018
• Subjects: Biochemistry, Genetics and Molecular Biology; Medicine
• Online Access: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84939444466&origin=inward; http://cmuir.cmu.ac.th/jspui/handle/6653943832/54195
• Institution: Chiang Mai University

© 2015 Informa Healthcare USA, Inc. We report the molecular and hematological feature of a Thai woman who had clinical diagnosis of β-thalassemia intermedia (β-TI). Hemoglobin (Hb) high performance liquid chromatography (HPLC) analysis identified Hb A (64.4%), Hb F (12.3%) and Hb A<inf>2</inf>/E (15.9%) with small peaks of Hb Barts (γ4) and Hb H (β4). She was initially diagnosed as EA Barts disease, which occurs from combination of Hb H disease and Hb E (HBB: c.79G > A) trait. However, the Hb analysis using capillary electrophoresis (CE) demonstrated no Hb E, 68.5% Hb A, 15.5% Hb F and 16.0% Hb A<inf>2</inf>. DNA analysis showed a compound heterozygosity for (β⁺)-31 (A > G) (HBB: c.-81A > G) and (β⁰) codon 17 (A > T) (HBB: c.52A > T) mutations and deletional Hb H (-^SEA/-α^3.7). Thus, she was finally diagnosed with a combination of Hb H disease and compound heterozygosity of β⁺/β⁰-thalassemia (β⁺/β⁰-thal). The β-globin mutations could affect not only hematological parameters but also elevate the Hb A<inf>2</inf> levels. These effects could not be ameliorated by the coinheritance of Hb H disease. Therefore, a better understanding of the effects of this combination on hematological analysis data will be useful for providing accurate diagnosis, genetic counseling, prevention and control programs of β-thalassemia major (β-TM).